Cellectis Competitors and Similar CompaniesClear all
Cellectis's competitors and similar companies include Allogene Therapeutics and UCB.
 Cellectis Cellectis is a clinical-stage biopharmaceutical company that develops cell and gene therapies. |  Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | |
Founding Date | Founding Date 1999 | Founding Date 2018 | Founding Date 1928 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Paris, FR HQ New York, US Raleigh, US | Locations South San Francisco, US HQ | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more |
Employees | Employees 216 | Employees 2263% decrease | Employees 9,052 |
Valuation ($) | Valuation ($) 189.4 m | Valuation ($) 585.5 m | Valuation ($) 34.3 b |
Financial | |||
Revenue (est.) | Revenue (est.) $72.9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) €7.4b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) |
Gross profit | Gross profit $80.2m (FY, 2025) | Gross profit N/A | Gross profit €7.2b (FY, 2025) |
Net income | Net income ($67.6m) (FY, 2025) | Net income ($190.9m) (FY, 2025) | Net income €1.6b (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 3.2m | Total funding raised $ 532m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Allogene Therapeutics
HQ
South San Francisco, US
Employees
226↓ 3% decrease
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
View companyUCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View company